These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28750150)

  • 1. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
    Quéreux G; Wylomanski S; Bouquin R; Saint-Jean M; Peuvrel L; Knol AC; Hanf M; Dréno B
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e39-e40. PubMed ID: 28750150
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
    Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
    [No Abstract]   [Full Text] [Related]  

  • 3. Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus.
    Maeda T; Yanagi T; Imafuku K; Kitamura S; Hata H; Izumi K; Ujiie H; Iwata H; Shimizu H
    Int J Dermatol; 2017 Dec; 56(12):1477-1479. PubMed ID: 28762466
    [No Abstract]   [Full Text] [Related]  

  • 4. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

  • 5. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
    Maeda T; Hiura A; Uehara J; Toyoshima R; Nakagawa T; Yoshino K
    Eur J Dermatol; 2021 Oct; 31(5):662-664. PubMed ID: 34642136
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
    Shoushtari AN; Bluth MJ; Goldman DA; Bitas C; Lefkowitz RA; Postow MA; Munhoz RR; Buchar G; Hester RH; Romero JA; Fitzpatrick LJ; Weiser MR; Panageas KS; Wolchok JD; Chapman PB; Carvajal RD
    Melanoma Res; 2017 Feb; 27(1):57-64. PubMed ID: 27792058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case of metastatic uveal melanoma in which an antitumor effect appeared after ipilimumab discontinuation due to autoimmune hypophysitis.
    Ohnuma T; Matsuzawa T; Kinoshita M; Sano S; Kawamura T; Shimada S; Inozume T
    J Dermatol; 2017 Nov; 44(11):1325-1326. PubMed ID: 27864834
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
    Naumann RW; Hollebecque A; Meyer T; Devlin MJ; Oaknin A; Kerger J; López-Picazo JM; Machiels JP; Delord JP; Evans TRJ; Boni V; Calvo E; Topalian SL; Chen T; Soumaoro I; Li B; Gu J; Zwirtes R; Moore KN
    J Clin Oncol; 2019 Nov; 37(31):2825-2834. PubMed ID: 31487218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.
    Machado MAÁ; de Moura CS; Chan K; Curtis JR; Hudson M; Abrahamowicz M; Jamal R; Pilote L; Bernatsky S
    Sci Rep; 2020 Sep; 10(1):14607. PubMed ID: 32884119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis.
    El Rassy E; Farhat F; Kattan J
    Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477
    [No Abstract]   [Full Text] [Related]  

  • 13. Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports.
    Schliep S; Agaimy A; Cavallaro A; Kiesewetter F; Schuler G; Heinzerling L
    J Immunother Cancer; 2018 Jan; 6(1):2. PubMed ID: 29332608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma.
    Nomura M; Oze I; Masuishi T; Yokota T; Satake H; Iwasawa S; Kato K; Andoh M
    Int J Clin Oncol; 2020 May; 25(5):972-977. PubMed ID: 31938955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.
    Yokota K; Uchi H; Uhara H; Yoshikawa S; Takenouchi T; Inozume T; Ozawa K; Ihn H; Fujisawa Y; Qureshi A; de Pril V; Otsuka Y; Weber J; Yamazaki N
    J Dermatol; 2019 Dec; 46(12):1197-1201. PubMed ID: 31638282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
    [No Abstract]   [Full Text] [Related]  

  • 17. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
    Br J Dermatol; 2018 Jul; 179(1):213-215. PubMed ID: 29405254
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab.
    Nomura M; Otsuka A; Yoshimura M; Nonomura Y; Kaku Y; Matsumoto S; Muto M
    Cancer Chemother Pharmacol; 2018 May; 81(5):823-827. PubMed ID: 29502140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.